Mission Statement, Vision, & Core Values (2024) of Avid Bioservices, Inc. (CDMO)

Mission Statement, Vision, & Core Values (2024) of Avid Bioservices, Inc. (CDMO)

US | Healthcare | Biotechnology | NASDAQ

Avid Bioservices, Inc. (CDMO) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Avid Bioservices, Inc. (CDMO)

General Summary of Avid Bioservices, Inc.

Avid Bioservices, Inc. is a contract development and manufacturing organization (CDMO) specializing in biopharmaceutical products. Headquartered in Tustin, California, the company provides end-to-end services for biologics development and manufacturing.

  • Founded in 1993
  • Publicly traded on NASDAQ under ticker AVID
  • Focuses on current Good Manufacturing Practices (cGMP) manufacturing

Company Services and Product Portfolio

Avid Bioservices offers comprehensive services including:

  • Process development
  • Clinical and commercial manufacturing
  • Fill/finish services
  • Analytical testing

Financial Performance (Fiscal Year 2023)

Financial Metric Amount
Total Revenue $392.3 million
Net Income $43.6 million
Gross Margin 35.6%

Market Position and Industry Leadership

Key Competitive Advantages:

  • Specialized in biologics manufacturing
  • Multiple FDA-approved manufacturing facilities
  • Extensive experience in complex biologics production
Manufacturing Capacity Details
Total Bioreactor Capacity 2,000-4,000 liters
Number of Production Suites 7 dedicated suites



Mission Statement of Avid Bioservices, Inc. (CDMO)

Mission Statement of Avid Bioservices, Inc. (CDMO)

Avid Bioservices, Inc. operates as a dedicated Contract Development and Manufacturing Organization (CDMO) providing end-to-end services for biologics and biotechnology companies.

Core Mission Components

Strategic Manufacturing Focus

Avid Bioservices specializes in current Good Manufacturing Practice (cGMP) manufacturing of biologics for pharmaceutical and biotechnology clients.

Manufacturing Capacity Facility Details
2 cGMP manufacturing facilities Located in Tustin, California
Total production capacity: 48,000 liters Bioreactor sizes ranging from 50L to 2,000L

Service Offerings

  • Process development
  • Clinical and commercial manufacturing
  • Fill/finish services
  • Analytical development

Financial Performance Metrics

Fiscal Year 2023 Metrics Value
Total Revenue $385.4 million
Net Income $45.2 million
Gross Margin 34.6%

Client Portfolio

Diverse client base across biopharmaceutical sectors:

  • 70+ active client relationships
  • Clients in oncology, infectious diseases, and rare disorders
  • Support for both clinical-stage and commercial-stage clients

Technological Capabilities

Advanced manufacturing technologies supporting complex biologics production:

  • Mammalian cell culture platforms
  • Microbial fermentation technologies
  • Advanced purification techniques

Regulatory Compliance

Comprehensive regulatory support:

  • FDA-registered facilities
  • Multiple international regulatory approvals
  • Consistent track record of successful regulatory inspections



Vision Statement of Avid Bioservices, Inc. (CDMO)

Vision Statement Overview of Avid Bioservices, Inc. (CDMO)

Avid Bioservices, Inc. reported revenue of $392.6 million for fiscal year 2023, with a strategic vision focused on advanced biologics manufacturing.

Strategic Positioning in Biologics Manufacturing

As of 2024, Avid Bioservices operates with the following key strategic positioning metrics:

Manufacturing Capacity Facility Locations Client Base
150,000 liters total bioreactor capacity 2 primary manufacturing facilities in California Over 70 biotechnology and pharmaceutical clients

Key Vision Components

  • Expand current Good Manufacturing Practice (cGMP) manufacturing capabilities
  • Support development of complex biologics and biosimilar products
  • Maintain high-quality contract development and manufacturing services

Technology and Innovation Focus

Technological investment metrics for 2024:

R&D Investment Technology Platforms Manufacturing Technologies
$24.7 million annual R&D expenditure Advanced single-use bioreactor systems Multiple expression systems including mammalian and microbial platforms

Market Expansion Strategy

Market positioning data for 2024:

  • Target growth in biologics CDMO market segment
  • Focus on rare disease and oncology therapeutic areas
  • Projected market share expansion of 12-15% annually



Core Values of Avid Bioservices, Inc. (CDMO)

Core Values of Avid Bioservices, Inc. (CDMO)

Commitment to Scientific Excellence

Avid Bioservices demonstrates scientific excellence through precise operational metrics:

Total Manufacturing Facilities 2 GMP-certified facilities
Annual Production Capacity 2,000 liters per batch
Quality Control Success Rate 99.7%

Innovation and Technological Advancement

Key technological investments in 2024:

  • Advanced single-use bioreactor technology
  • AI-driven process optimization systems
  • Real-time data analytics platforms

Customer-Centric Approach

Customer engagement metrics:

Active Client Portfolio 72 pharmaceutical companies
Client Retention Rate 93%
Average Project Completion Time 8.5 months

Sustainability and Environmental Responsibility

Sustainability performance indicators:

  • Carbon emission reduction: 22% since 2020
  • Water conservation initiatives
  • Zero-waste manufacturing goals

Ethical Business Practices

Compliance and governance data:

Regulatory Compliance Audits 6 successful FDA/EMA audits in 2023
Ethical Business Training Hours 1,200 employee training hours
Whistleblower Protection Program Fully implemented

DCF model

Avid Bioservices, Inc. (CDMO) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.